Use of bisphosphonates in a case of perthes disease

Orthopaedic Nursing

Volumn 24, Issue 6, 2003, Pages 393-398

  McQuade, Mary ^a   Houghton, Kerry ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85026147080     PISSN: 07446020     EISSN: 1542538X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Alexander, M. (2002). Congenital and developmental disorders. In A. B. Maher, S. W. Salmond, & T. A. Pellino (Eds.), Orthopaedic Nursing (3rd ed., pp. 567-570). Philadelphia: W. B. Saunders.
2. Bronson, W. E. (2001). The pediatric hip. Current Opinion in Orthopaedic, 12(6), 470-479.
3. Carney, B. T., & Minter, C. L. (2004). Nonsurgical treatment to regain hip abduction motion in Perthes disease: A retrospective review. Southern Medical Journal, 97(5), 485-488.
4. Fleisch, H. (2000). Bisphosphonates-preclinical. In Bisphosphonates in Bone Disease. From the Laboratory to the Patient, (4th ed., pp. 27-55) London: Academic Press.
5. Gigante, C., Frizziero, P., & Turra, S. (2002). Prognostic value of catterall and herring classification in Legg-Calve-Perthes disease: Follow-up to skeletal maturity of 32 patients. Journal of Pediatric Orthopaedics, 22(3), 345-349.
6. Glorieux, F. H., Bishop, N. J., Plotkin, H., Chabot, G., Lanoue, G., & Travers, R. (1998). Cyclic administration of pamidronate in children with severe Osteogenesis Imperfecta. New England Journal of Medicine, 339(14), 947-952.
7. Herring, J. A., Neustadt, J. B., Williams, J. J., Early, J. S., & Browne, R. H. (1992). The lateral pillar classification of Legg-Calve-Perthes disease. Journal of Pediatric Orthopaedics, 12(2), 143-50.
8. Herring, J. A., (2002). Legg-Calve-Perthes disease. In Tachdjian's pediatric orthopaedics, from the Texas Scottish Rite Hospital for Children. Vol 1, (3rd ed., pp. 655-709). Philadelphia. Saunders.
9. Herring, J. A., Kim, H. T., & Browne R., (2004). Legg-Calve-Perthes disease. Part II: Prospective multicenter study of the effect of treatment on outcome. Journal of Bone Joint Surgery America, 86-A(10), 2121-2134.
10. Hogler, W., Yap, F., Little, D., Ambler, G., McQuade, M., & Cowell, C. (2004). Short-term safety assessment in the use of intravenous zoledronic acid in children. Journal of Pediatrics, 145, 701-704.
11. Joseph, B., Nair, S. N., Rao, K. L., Narasimha., Mulpuri, K., & Varghese, G. (2003). Optimal timing for containment surgery for Perthes Disease. Journal of Pediatric Orthopaedics, 23(5), 601-606.
12. Larson, P., Kronenberg, H., Melmed, S., & Polonsky, K. (2003). 26 hormones and disorders of mineral disorders and mineral metabolism. In R. H. William (Ed.), Williams textbook of endocrinology (10th ed., pp. 1303-1322). Philadelphia: Saunders.
13. Lipton, A. (2003). Management of metastatic bone disease and hypercalcemia of malignancy. American Journal of Cancer, 2(6), 427-438.
14. Rauch, F., & Glorieux, F. (2004). Osteogenesis imperfecta. The Lancet, 363, 1377-1385.
15. Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., & et al. (2002). Intravenous zoledronic acid in postmenopausal women with low mineral density. New England Journal of Medicine, 346, 653-661.